PHASE II TRIAL OF FOLFIRI REGIMEN PLUS BEVACIZUMAB ALTERNATED WITH OXALIPLATIN-BASED HEPATIC ARTERIAL INFUSION PLUS DE GRAMONT REGIMEN AND BEVACIZUMAB IN THE TREATMENT OF UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Primary objectives: TUMOR RESPONSE RATE (RR)
创建时间：
2007-05-15
